An observational study in Small-cell Lung Cancer and Extensive-stage Small-cell Lung Cancer, sponsored by Hellenic Cooperative Oncology Group. Active, not recruiting at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Hellenic Cooperative Oncology Group · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Small Cell Lung Carcinoma with a site in Greece — 10 open to participants now, 22 under way, 16 of them phase 3. Small Cell Lung Carcinoma · Greece.
Among the 36 studies in Small Cell Lung Carcinoma with a site in Greece, this one is one of 4 that started in 2021, is one of 3 observational ones, reaches primary completion later than 3 of the 21 other live ones, and was the 20th registered.
1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →10 of the 36 studies in Small Cell Lung Carcinoma with a site in Greece are open now. Recruiting first, the newest first:
SystImmune Inc. · Sites in Greece, United States, Australia and 13 more countries
Ages 18+
AbbVie · Sites in Greece, United States, Austria and 7 more countries
Ages 18+
Boehringer Ingelheim · Sites in Greece, United States, Argentina and 39 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Greece, United States, Argentina and 10 more countries
Ages 18+
Zai Lab (Shanghai) Co., Ltd. · Sites in Greece, United States, Austria and 12 more countries
Ages 18+
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 24
First in 1998; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 137 across 144 observational studies indexed under Small Cell Lung Carcinoma.
Median enrollment 480 across the 33 interventional studies, 111 across the 3 observational. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 10 most frequent:
Hellenic Cooperative Oncology Group is the lead sponsor of 62 studies on the registry; 6 are open to participants now.
Hellenic Cooperative Oncology Group has 2 studies filed under Small Cell Lung Carcinoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Small Cell Lung Carcinoma with a site in Greece that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06646276Phase 3Bristol-Myers SquibbA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | 2027-08-17 |
| NCT04624204Phase 3Merck Sharp & Dohme LLCPlacebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | 2027-10-28 |
| NCT07099898Phase 3GlaxoSmithKlineA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] | 2027-11-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Small Cell Lung Carcinoma with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a non-interventional, multicenter, prospective observational study and registry of standard clinical practice in patients with Extensive Stage-Small Cell Lung Cancer (ES-SCLC) receiving 1st line treatment with Durvalumab in combination with standard chemotherapy (cisplatin or carboplatin + etoposide) in the approved indication, which will be carried out in Greece. In this study data will be collected prospectively based on real-world clinical practice. A prospective cohort of atients from centers of the Hellenic Cooperative Oncology Group (HeCOG) will be included. The study will be conducted in hospitals and by physicians specialized in lung cancer from different geographical areas of Greece.
In this observational prospective study, no changes to current therapeutic practice will be required and all aspects of treatment and clinical management of patients will be in compliance with the local clinical practice and will be left to the discretion of the participating physicians. Patients will be treated in accordance with the study medicine's local prescribing information and standard clinical practice as to the frequency of visits and types of evaluations carried out. The frequency of follow-up visits is set on the basis of standard practice; however, the study-related data will be collected during integration and during the routine clinical visits that will take place after the start of treatment. No visits or measurement/evaluation will be mandatory by the protocol and data collection at the predetermined time-points will be carried out only if the patient visits the center.
Patients will be enrolled during a 12-month recruitment period from HeCOG-participating public and private centers/clinics in Greece with specialization in lung cancer. As part of this study, participating physicians will be asked to follow up each patient for an additional 12 months of treatment at most after last subject is included, or until death, withdrawal of consent, discontinuation of treatment or initiation of new antineoplastic therapy, until completion of the study, or doctor's decision, whichever appears first. Therefore, the maximum period of prospective observation of the study will be 24 months (2 years) from the last patient enrolled in the study. This study will be conducted in accordance with the Guidelines for Good Pharmacoepidemiological Practice, the European General Data Protection Regulation (GDPR) and the applicable regulatory requirements.
Patients with Small- Cell Lung Cancer candidates for 1st- line immunotherapy plus platinum based chemotherapy (cisplatin or carboplatin plus etoposide) currently with active disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
extensive small-cell lung cancer
This study also gives DurvalumabStudies of DurvalumabDurvalumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Overall survival rates (OS)
The primary objective of the study is to estimate the overall survival rates (OS) at 6,12 and 24 months for patients with extensive small-cell lung cancer treated with Durvalumab in combination with standard 1st-line chemotherapy with platinum-etoposide(cisplatin or carboplatin).
Time frame: up to 24 months
Progression free survival (PFS)
Evaluation of PFS from investigator
Time frame: in 6, 12 and up to 24 months
Overall response rate (ORR)
Time frame: in 6 and up to 12 months
Disease Control Rate
Time frame: in 6 and up to 12 months
time to reach a response (TTR)
Time frame: up to 12 months
duration of the response (DoR)
Time frame: up to 12 months
Assessment of patients characteristics with overall survival 12 months
Time frame: up to 12 months
Assessment of patients characteristics with overall survival 24 months
Time frame: up to 24 months
time under treatment (ToT)
Time frame: up tp 24 months
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 with standard of care 1st line treatment
Time frame: From date of Informed Consent signatory and every 3 weeks, up to 24 months
Quality of life EQ-5D
Time frame: From date of Informed Consent signatory and every 2 months, up to 24 months
number of participants using health resources in daily clinical practice
Time frame: From date of Informed Consent signatory and every 3 weeks, up to 24 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2021 to primary completion in Jan 2026, 57 months.
Of 62 observational studies under Small Cell Lung Carcinoma, half reached primary completion within 77 months of starting (the median), counting those still running; a quarter within 47. This study's 57 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Apr 2023 → Jan 2026 and completion Apr 2024 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hellenic Cooperative Oncology Group